<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049174</url>
  </required_header>
  <id_info>
    <org_study_id>270267</org_study_id>
    <nct_id>NCT05049174</nct_id>
  </id_info>
  <brief_title>Nurse-led Smoking Cessation Program With Follow-up in Healthy Life Centres: a Randomized Clinical Trial</brief_title>
  <official_title>Clinical and Health-economic Effects of a Nurse-led Smoking Cessation Program With Follow-up in Healthy Life Centres With Free Cessation Drugs: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Directorate of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vestre Viken Hospital Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A better understanding of how to incorporate effective smoking cessation into clinical&#xD;
      practice is requested. In this is prospective, multi-center, randomized, open, blinded&#xD;
      end-point trial, we assigned daily smokers hospitalized with an acute cardiac event 1:1 to an&#xD;
      in-hospital nurse-led smoking cessation intervention with direct referral to further&#xD;
      follow-up in the municipal healthy life-centres (intensive intervention) or to written&#xD;
      information about smoking cessation and the municipal program (low-threshold intervention) .&#xD;
      The primary outcome will be the smoking cessation rates between the groups at 6 months&#xD;
      follow-up. Key secondary outcomes include a cost-effectiveness analysis of the intensive&#xD;
      intervention and cessation rates at 3- and 12-months follow-up, the proportion who used&#xD;
      varenicline or nicotine replacement therapy and the proportion who attended the healthy-life&#xD;
      center program between the two groups. Exploratory analyses include new knowledge about the&#xD;
      patient and system factors of importance for participation to healthy life-centers and for&#xD;
      changes in smoking behaviour.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants were randomized 1:1 to an in-hospital nurse-led smoking cessation intervention with systematic referrral to the municipal healthy life-centres or to written information about smoking cessation and the municipal health service program.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between the groups in point prevalence of self-report smoking abstinence at six months follow-up</measure>
    <time_frame>Six months after randomization</time_frame>
    <description>Difference between the groups in the proportion of participants who self-report smoking abstinence over the whole follow-up period at six months follow-up allowing up to five cigarettes in total</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between the groups in proportion who quit smoking determined with objectively</measure>
    <time_frame>Six months after randomization</time_frame>
    <description>Difference between the groups in proportion of participants who quit smoking measured by the level of carbon monoxide in the exhaled air</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between the groups in point prevalence of self-report smoking abstinence three months after randomization</measure>
    <time_frame>Three months after randomization</time_frame>
    <description>Difference between the groups in the proportion of participants who self-report smoking abstinence over the whole periode follow-up period at six months follow-up allowing up to five cigarettes in total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between the groups in point prevalence of self-report smoking abstinence 12 months after randomization</measure>
    <time_frame>Twelve months after randomization</time_frame>
    <description>Difference between the groups in the proportion of participants who self-report smoking abstinence over the whole periode follow-up period at six months follow-up allowing up to five cigarettes in total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in participation rate at healthy life-centres between the groups</measure>
    <time_frame>8 to 12 weeks after randomization</time_frame>
    <description>Differences in participation rate at healthy life-centres between the groups measured by telephone interview with personnell at the healthy life-centres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in use of smoking cessation aids between the groups</measure>
    <time_frame>8 to 12 weeks after randomization</time_frame>
    <description>Differences in the proportion of patients who use of smoking cessation aids (varenicline or nicotine replacement therapy) between the groups measured by patient self-report</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Differences in changes in clinical and psychological factors between the study groups</measure>
    <time_frame>From baseline until 6 months follow-up</time_frame>
    <description>Differences between the study groups in the proportion of participants who report significant changes in clinical and psychological factors from baseline until six months follow-up measured by patient self-report</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Smoking Behaviors</condition>
  <condition>Nurse's Role</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Intensive intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-threshold intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nuse-led interview and referral to municipal healthy life-centres</intervention_name>
    <description>Usual care treatment and written information to patients and general practitionnaires about smoking cessation and the municipal healthy life-centres</description>
    <arm_group_label>Intensive intervention</arm_group_label>
    <arm_group_label>Low-threshold intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years and smokes at least 1 cigarette daily&#xD;
&#xD;
          -  Hospitalized with an acute cardiovascular event (i.e. myocardial infarction, unstable&#xD;
             or stable angina, arrythmias, carotid stenosis or claudication with need for&#xD;
             revascularization)&#xD;
&#xD;
          -  Sign informed consent and is expected to participate according to ICH / GCP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Does not usually live or work in the Vestre Viken catchment area&#xD;
&#xD;
          -  Chronic renal failure stage 4 or known allergic reaction to varenicline&#xD;
&#xD;
          -  Any condition (e.g. psychosis, alcohol abuse, dementia) or situation that may pose a&#xD;
             significant risk to the participant, confuse the results or make participation&#xD;
             unethical&#xD;
&#xD;
          -  Lack of Norwegian and English knowledge&#xD;
&#xD;
          -  Short life expectancy (&lt;12 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Munkhaugen, MD, PhD</last_name>
    <phone>+47 97524194</phone>
    <email>johmun@vestreviken.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elise Sverre, MD, PhD</last_name>
    <phone>+47 99020329</phone>
    <email>elisbj@vestreviken.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <state>Viken</state>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Munkhaugen, MD, PhD</last_name>
      <phone>+4797524194</phone>
      <email>johmun@vestreviken.no</email>
    </contact>
    <contact_backup>
      <last_name>Elise Sverre, MD, PhD</last_name>
      <phone>+4799020329</phone>
      <email>elisbj@vestreviken.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ringerike Hospital</name>
      <address>
        <city>HÃ¸nefoss</city>
        <state>Viken</state>
        <zip>3511</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Stugaard, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kongsberg Hospital</name>
      <address>
        <city>Kongsberg</city>
        <state>Viken</state>
        <zip>3612</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohpal Kahlon, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

